Biopharmaceutical company Foresee Pharmaceuticals (TPEx:6576) announced on Sunday that it has successfully completed its Phase 1 single and multiple ascending dose clinical study in Australia for linvemastat (FP-020), a selective oral MMP-12 inhibitor.
The trial evaluated safety, tolerability, and pharmacokinetics in healthy subjects, with 40 participants in the single dose phase and 24 in the multiple dose phase.
Linvemastat is designed to treat inflammatory and fibrotic diseases, offering greater potency and selectivity than its predecessor, aderamastat (FP-025). Preclinical studies show favorable efficacy in respiratory and inflammatory bowel diseases. MMP-12, a key immune-fibrotic modulator, is linked to disease severity in asthma and COPD. Foresee plans to advance linvemastat for respiratory and fibrotic conditions.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study